LT2361936T - Antigeną rišanti molekulė ir jos panaudojimas - Google Patents

Antigeną rišanti molekulė ir jos panaudojimas

Info

Publication number: LT2361936T
Authority: LT; Lithuania
Prior art keywords: antigen; binding molecule; molecule; binding
Prior art date: 2010-02-25

Application number

LTEP10154751.1T

Other languages

English (en)

Inventor

Melvyn Little

Fabrice Le Gall

Original Assignee

Affimed Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-02-25

Filing date

2010-02-25

Publication date

2016-09-12

2010-02-25 Application filed by Affimed Gmbh filed Critical Affimed Gmbh

2016-09-12 Publication of LT2361936T publication Critical patent/LT2361936T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Life Sciences & Earth Sciences (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

LTEP10154751.1T 2010-02-25 2010-02-25 Antigeną rišanti molekulė ir jos panaudojimas LT2361936T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP10154751.1A EP2361936B1 (en)	2010-02-25	2010-02-25	Antigen-binding molecule and uses thereof

Publications (1)

Publication Number	Publication Date
LT2361936T true LT2361936T (lt)	2016-09-12

Family

ID=42232726

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP10154751.1T LT2361936T (lt)	2010-02-25	2010-02-25	Antigeną rišanti molekulė ir jos panaudojimas
LTEP11156113.0T LT2371866T (lt)	2010-02-25	2011-02-25	Daugiavalentė antigeną rišanti fv molekulė

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LTEP11156113.0T LT2371866T (lt)	2010-02-25	2011-02-25	Daugiavalentė antigeną rišanti fv molekulė

Country Status (12)

Country	Link
EP (2)	EP2361936B1 (lt)
DK (1)	DK2371866T3 (lt)
ES (2)	ES2582001T3 (lt)
HR (1)	HRP20190288T1 (lt)
HU (1)	HUE041615T2 (lt)
LT (2)	LT2361936T (lt)
PL (2)	PL2361936T3 (lt)
PT (2)	PT2361936T (lt)
RS (1)	RS58352B1 (lt)
SI (1)	SI2371866T1 (lt)
SM (1)	SMT201900115T1 (lt)
TR (1)	TR201902400T4 (lt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2011373925B2 (en) *	2011-07-22	2016-04-28	Affimed Therapeutics Ag	Multivalent antigen-binding Fv molecule
EP2970449B1 (en) *	2013-03-15	2019-09-25	Amgen Research (Munich) GmbH	Single chain binding molecules comprising n-terminal abp
AP2016009586A0 (en)	2014-05-29	2016-11-30	Macrogenics Inc	Tri-specific binding molecules and methods of use thereof
EP3164417A1 (en)	2014-07-01	2017-05-10	Pfizer Inc.	Bispecific heterodimeric diabodies and uses thereof
AU2015339032B2 (en) *	2014-10-31	2020-02-20	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Tetravalent TLR9 bispecific antibody
TWI688572B (zh)	2015-01-26	2020-03-21	美商宏觀基因股份有限公司	包含dr5-結合結構域的多價分子
EP3466967A1 (en)	2015-05-18	2019-04-10	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
TWI773646B (zh)	2015-06-08	2022-08-11	美商宏觀基因股份有限公司	結合lag-3的分子和其使用方法
GEAP202215554A (en)	2015-07-30	2022-06-10	Macrogenics Inc	Pd-1-binding molecules and methods of use thereof
MX2018007089A (es)	2015-12-14	2019-01-30	Macrogenics Inc	Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas.
US20170233472A1 (en)	2016-02-17	2017-08-17	Macrogenics, Inc.	ROR1-Binding Molecules, and Methods of Use Thereof
CA3020864A1 (en)	2016-04-15	2017-10-19	Macrogenics, Inc.	Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
US11242376B2 (en)	2016-08-02	2022-02-08	TCR2 Therapeutics Inc.	Compositions and methods for TCR reprogramming using fusion proteins
GB2564823B8 (en)	2016-10-07	2022-06-29	Tcr2 Therapeutics Inc	Compositions and methods for TCR reprogramming using fusion proteins
CA3044593A1 (en)	2016-11-22	2018-05-31	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
WO2018119166A1 (en)	2016-12-23	2018-06-28	Macrogenics, Inc.	Adam9-binding molecules, and methods of use thereof
JP7115758B2 (ja)	2017-02-28	2022-08-09	アッフィメッド・ゲー・エム・ベー・ハー	Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ
EA201991632A1 (ru) *	2017-02-28	2020-03-12	Аффимед Гмбх	Комбинация антитела против cd16a с цитокином
RU2020122822A (ru)	2017-12-12	2022-01-13	Макродженикс, Инк.	Биспецифичные связывающие cd16 молекулы и их применение при лечении заболеваний
EP3752196A4 (en)	2018-02-15	2022-03-23	MacroGenics, Inc.	CD3-BINDING DOMAIN VARIANTS AND THEIR USE IN COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES
MX2020010728A (es) *	2018-04-13	2020-11-06	Affimed Gmbh	Constructos de fusion de anticuerpos que se acoplan a celulas nk.
CN113874398B (zh)	2019-05-21	2025-08-01	诺华股份有限公司	Cd19结合分子及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5837242A (en)	1992-12-04	1998-11-17	Medical Research Council	Multivalent and multispecific binding proteins, their manufacture and use
DE19819846B4 (de)	1998-05-05	2016-11-24	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Multivalente Antikörper-Konstrukte
DE10060140A1 (de) *	2000-12-04	2002-06-06	Vectron Therapeutics Ag Imt	Multimerer mehrfach-antigenbindender einzelkettiger Antikörper
EP1500665B1 (en) *	2002-04-15	2011-06-15	Chugai Seiyaku Kabushiki Kaisha	METHODS FOR CONSTRUCTING scDb LIBRARIES
EP1400534B1 (en)	2002-09-10	2015-10-28	Affimed GmbH	Human CD3-specific antibody with immunosuppressive properties
GB0510790D0 (en)	2005-05-26	2005-06-29	Syngenta Crop Protection Ag	Anti-CD16 binding molecules

2010
- 2010-02-25 LT LTEP10154751.1T patent/LT2361936T/lt unknown
- 2010-02-25 ES ES10154751.1T patent/ES2582001T3/es active Active
- 2010-02-25 PL PL10154751.1T patent/PL2361936T3/pl unknown
- 2010-02-25 EP EP10154751.1A patent/EP2361936B1/en active Active
- 2010-02-25 PT PT101547511T patent/PT2361936T/pt unknown
2011
- 2011-02-25 RS RS20190201A patent/RS58352B1/sr unknown
- 2011-02-25 EP EP11156113.0A patent/EP2371866B1/en active Active
- 2011-02-25 HU HUE11156113A patent/HUE041615T2/hu unknown
- 2011-02-25 PT PT11156113T patent/PT2371866T/pt unknown
- 2011-02-25 SI SI201131675T patent/SI2371866T1/sl unknown
- 2011-02-25 SM SM20190115T patent/SMT201900115T1/it unknown
- 2011-02-25 PL PL11156113T patent/PL2371866T3/pl unknown
- 2011-02-25 TR TR2019/02400T patent/TR201902400T4/tr unknown
- 2011-02-25 DK DK11156113.0T patent/DK2371866T3/en active
- 2011-02-25 LT LTEP11156113.0T patent/LT2371866T/lt unknown
- 2011-02-25 ES ES11156113T patent/ES2711377T3/es active Active
2019
- 2019-02-13 HR HRP20190288TT patent/HRP20190288T1/hr unknown

Also Published As

Publication number	Publication date
SI2371866T1 (sl)	2019-04-30
TR201902400T4 (tr)	2019-03-21
PT2361936T (pt)	2016-07-15
EP2371866B1 (en)	2018-11-21
LT2371866T (lt)	2019-03-12
PL2371866T3 (pl)	2019-05-31
DK2371866T3 (en)	2019-03-18
EP2361936A1 (en)	2011-08-31
ES2711377T3 (es)	2019-05-03
SMT201900115T1 (it)	2019-02-28
EP2361936B1 (en)	2016-04-20
RS58352B1 (sr)	2019-03-29
HUE041615T2 (hu)	2019-05-28
EP2371866A3 (en)	2013-06-26
HRP20190288T1 (hr)	2019-04-05
ES2582001T3 (es)	2016-09-08
PT2371866T (pt)	2019-02-27
PL2361936T3 (pl)	2016-10-31
EP2371866A2 (en)	2011-10-05

Publication	Publication Date	Title
PL2361936T3 (pl)	2016-10-31	Cząsteczka wiążąca antygen i jej zastosowania
DK2729170T3 (en)	2022-03-21	Antibody variants and uses thereof
HUE040213T2 (hu)	2019-02-28	Anti-TIM antitest
PL2530091T3 (pl)	2018-08-31	Przeciwciało przeciwko dll3
LT2946791T (lt)	2022-01-10	Anti-cd277 antikūnai ir jų panaudojimas
PL2616489T3 (pl)	2017-07-31	Przeciwciało anty-huTNFR1
IL222852A0 (en)	2012-12-31	Anti-fgfr2 antibodies
GB201000467D0 (en)	2010-02-24	Antibodies
IL221371A0 (en)	2012-10-31	Anti-lrp6 antibodies
IL229844B (en)	2022-02-01	Anti-psgl-1 antibodies and their use
LT2531518T (lt)	2016-09-26	Oligopeptidiniai dariniai ir jų panaudojimas
GB201020738D0 (en)	2011-01-19	Antibodies
IL225571A0 (en)	2013-06-27	Antibodies
GB201002238D0 (en)	2010-03-31	Antibodies
GB201106357D0 (en)	2011-06-01	Composition and uses thereof
EP2716359A4 (en)	2014-04-23	COMPLEX AND USES THEREOF
GB201111775D0 (en)	2011-08-24	Compounds and uses thereof
GB201007957D0 (en)	2010-06-30	Antibody
AU4935P (en)	2014-10-21	FerrupenGL Pimelea ferruginea
GB201014319D0 (en)	2010-10-13	Compounds and uses thereof
GB201115285D0 (en)	2011-10-19	Biosensor and uses thereof
GB201017780D0 (en)	2010-12-01	Antibody
GB201013665D0 (en)	2010-09-29	Molecules
GB201121726D0 (en)	2012-02-01	Compounds and uses thereof
GB201121551D0 (en)	2012-01-25	Compounds and uses thereof